Commonwealth Equity Services Inc purchased a new stake in TESARO Inc (NASDAQ:TSRO) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,722 shares of the biopharmaceutical company’s stock, valued at approximately $222,000.
Several other large investors have also recently modified their holdings of the stock. Janus Henderson Group PLC purchased a new stake in TESARO in the 2nd quarter worth approximately $100,301,000. PointState Capital LP purchased a new stake in TESARO in the 2nd quarter worth approximately $85,971,000. Pictet Asset Management Ltd. lifted its position in TESARO by 58.1% in the 3rd quarter. Pictet Asset Management Ltd. now owns 630,904 shares of the biopharmaceutical company’s stock worth $81,450,000 after buying an additional 231,799 shares in the last quarter. Pioneer Investment Management Inc. lifted its position in TESARO by 195.6% in the 2nd quarter. Pioneer Investment Management Inc. now owns 317,753 shares of the biopharmaceutical company’s stock worth $44,441,000 after buying an additional 210,273 shares in the last quarter. Finally, BlackRock Inc. lifted its position in TESARO by 5.7% in the 2nd quarter. BlackRock Inc. now owns 3,605,247 shares of the biopharmaceutical company’s stock worth $504,230,000 after buying an additional 195,590 shares in the last quarter.
TESARO Inc (NASDAQ:TSRO) opened at $86.44 on Tuesday. TESARO Inc has a 12 month low of $79.03 and a 12 month high of $192.94. The company has a quick ratio of 4.35, a current ratio of 4.73 and a debt-to-equity ratio of 0.34.
A number of equities research analysts have issued reports on TSRO shares. Morgan Stanley reiterated an “overweight” rating and issued a $183.00 target price on shares of TESARO in a research report on Thursday, August 10th. Robert W. Baird restated a “neutral” rating and set a $140.00 price target (down previously from $155.00) on shares of TESARO in a research note on Thursday, August 10th. Evercore ISI started coverage on shares of TESARO in a research note on Wednesday, August 16th. They set an “in-line” rating and a $121.00 price target on the stock. Credit Suisse Group set a $190.00 price target on shares of TESARO and gave the stock a “buy” rating in a research note on Friday, August 18th. Finally, Jefferies Group set a $124.00 price target on shares of TESARO and gave the stock a “hold” rating in a research note on Thursday, August 17th. Two analysts have rated the stock with a sell rating, ten have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. TESARO currently has a consensus rating of “Buy” and a consensus target price of $159.39.
In other TESARO news, VP Edward C. English sold 10,862 shares of the firm’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $134.92, for a total value of $1,465,501.04. Following the sale, the vice president now directly owns 6,258 shares in the company, valued at approximately $844,329.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Martin H. Jr. Huber sold 592 shares of the firm’s stock in a transaction on Friday, September 22nd. The stock was sold at an average price of $118.60, for a total transaction of $70,211.20. Following the completion of the sale, the senior vice president now owns 6,943 shares in the company, valued at $823,439.80. The disclosure for this sale can be found here. Insiders sold a total of 21,454 shares of company stock worth $2,707,012 over the last quarter. 34.60% of the stock is currently owned by company insiders.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
What are top analysts saying about TESARO Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for TESARO Inc and related companies.